Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
Mon, November 7, 2022
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
Kevin Steinke Maintained (CCRN) at Buy with Increased Target to $45 on, Nov 7th, 2022
Kevin Steinke of Barrington Research, Maintained "Cross Country Healthcare, Inc." (CCRN) at Buy with Increased Target from $41 to $45 on, Nov 7th, 2022.
Kevin has made no other calls on CCRN in the last 4 months.
There are 2 other peers that have a rating on CCRN. Out of the 2 peers that are also analyzing CCRN, 1 agrees with Kevin's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tobey Sommer of "Truist Securities" Downgraded from Strong Buy to Hold and Held Target at $36 on, Wednesday, October 5th, 2022
This is the rating of the analyst that currently disagrees with Kevin
- Bill Sutherland of "Benchmark" Maintained at Strong Buy with Increased Target to $42 on, Thursday, September 15th, 2022
